Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Article Details

Authors
Sonia Brugnara, Mariacristina Sicher, Elena Maria Bonandini, Davide Donner, Franca Chierichetti, Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo

Article Type
Case Report

DOI
10.7573/dic.212515

Related Articles

Article Page

Abstract

Here, we report the case of a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient’s decision. To date October 2017, 18 months after the interruption of the treatment with the combination of dabrafenib and trametinib, follow-up Positron Emission Tomography (PET) scans are still documenting complete metabolic response.

Keywords: case report, complete remission, dabrafenib, drug combination, melanoma, neoplasm metastasis, vemurafenib.

Citation: Brugnara S, Sicher M, Bonandini EM, Donner D, Chierichetti F, Barbareschi M, Girardelli CR, Caffo O. Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. Drugs in Context 2018; 7: 212515. DOI: 10.7573/dic.212515

Disclosure and potential conflicts of interest: The authors declare no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at: https://www.drugsincontext.com/wp-content/uploads/2018/01/dic.212515-COI.pdf

Acknowledgements: Medical writing was performed by Luca Giacomelli and Lilia Biscaglia on behalf of Content Ed Net.

Funding declaration: Editorial assistance for this paper was supported by Novartis (Switzerland).

Copyright: Copyright © 2018 Brugnara S, Sicher M, Bonandini EM, Donner D, Chierichetti F, Barbareschi M, Girardelli CR, Caffo O. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Brugnara S, Sicher M, Bonandini EM, Donner D, Chierichetti F, Barbareschi M, Girardelli CR, Caffo O. https://doi.org/10.7573/dic.212515. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/treatment-combined-dabrafenib-trametinib-brafv600e-mutated-metastatic-malignant-melanoma-case-long-term-complete-response-treatment-cessation

Correspondence: Sonia Brugnara, Oncology Unit, S. Chiara Hospital, Trento, Italy. sonia.brugnara@apss.tn.it

Provenance: submitted; externally peer reviewed.

Submitted: 10 November 2017; Peer review comments to author: 15 December 2017; Revised manuscript received: 25 January 2018; Accepted: 26 January 2018; Publication date: 15 February 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF